A Combination of Novel NSC Small Molecule Inhibitor Along with Doxorubicin Inhibits Proliferation of Triple-Negative Breast Cancer through Metabolic Reprogramming

Scientists reported the discovery of a novel small molecule inhibitor (NSC33353) with potent anti-tumor activity against TNBC cells. The anti-proliferative effects of this small molecule inhibitor were determined using 2D and 3D cell proliferation assays.